Genfit : Le juge de paix d’ici à fin mai
>Une hausse des frais de SG&A mais une trésorerie solide - Suite à la publication de ses résultats annuels 2019, la société organisait une conférence téléphonique pour revenir sur les principaux points annoncés et notamment le décalage du dépôt d’enregistrement. Revenons tout d’abord sur les aspects financiers. La trésorerie actuelle s’établit à 277 M€ ce qui permet d’anticiper le début de la seconde histoire à savoir le potentiel lancement d’elafibranor. Soulignons l...Genfit is a biopharmaceutical company engaged in the discovery and development of drugs and biomarkers in therapeutic areas of high unmet need due to the lack of effective treatments or diagnostic tools and/or due to the increasing number of patients worldwide. Co. concentrates its research and development efforts to participate in the commercialization of treatment solutions and diagnostic tools to fight certain metabolic, inflammatory, autoimmune or fibrotic diseases affecting especially the liver (such as non-alcoholic steatohepatitis or "NASH").
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.